Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hansoh Pharma
Biotech
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
Regeneron’s partner reported Zepbound-like efficacy in a phase 3 trial, de-risking a part of the biotech’s differentiated play for the obesity space.
Nick Paul Taylor
Mar 9, 2026 8:25am
GSK says 'stay tuned' for more ADC data as Hansoh posts 49% ORR
Oct 19, 2025 10:40am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Regeneron pens $2B pact for Hansoh's potential rival to Zepbound
Jun 2, 2025 8:20am
Silence slows zerlasiran, as Hansoh leaves $1.3B biobucks collab
Feb 27, 2025 8:51am
Merck pays $112M upfront for Hansoh's preclinical GLP-1
Dec 18, 2024 7:44am
